Cargando…
Mapping Epitopes Recognised by Autoantibodies Shows Potential for the Diagnosis of High-Grade Serous Ovarian Cancer and Monitoring Response to Therapy for This Malignancy
SIMPLE SUMMARY: Most women are diagnosed with high-grade serous ovarian cancer (HGSOC) at stage III, when the cancer has already spread, contributing to poor survival outcomes. However, while earlier diagnosis increases survival rates, there is a lack of early diagnosis biomarkers. Previously, autoa...
Autores principales: | Moody, Rhiane, Wilson, Kirsty, Kampan, Nirmala Chandralega, McNally, Orla M., Jobling, Thomas W., Jaworowski, Anthony, Stephens, Andrew N., Plebanski, Magdalena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8392293/ https://www.ncbi.nlm.nih.gov/pubmed/34439354 http://dx.doi.org/10.3390/cancers13164201 |
Ejemplares similares
-
Pre-operative sera interleukin-6 in the diagnosis of high-grade serous ovarian cancer
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2020) -
Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2015) -
Combining TNFR2-Expressing Tregs and IL-6 as Superior Diagnostic Biomarkers for High-Grade Serous Ovarian Cancer Masses
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2023) -
Interleukin 6 Present in Inflammatory Ascites from Advanced Epithelial Ovarian Cancer Patients Promotes Tumor Necrosis Factor Receptor 2-Expressing Regulatory T Cells
por: Kampan, Nirmala Chandralega, et al.
Publicado: (2017) -
Natural Compounds with Potential to Modulate Cancer Therapies and Self-Reactive Immune Cells
por: Moody, Rhiane, et al.
Publicado: (2020)